On-Demand Online Seminar:
"Profil - the leading CRO for metabolic research"
Insights from Dr. Lars Bochmann, Director Marketing & Business Development at Profil:
You will benefit by learning about:
- An overview of what makes Profil the partner of choice for early phase clinical trials
- Profil's particular strengths in conducting early phase clinical trials in diabetes
- The vast methodological portfolio that Profil offers
Online Seminar synopsis
Profil is the world’s leading CRO in clinical metabolic research. As a full-service provider, we offer all services from designing the study to writing up the results.
We are the experts for early phase clinical trials within the indications of obesity, diabetes, and diabetes complications allowing us to design and carry out best-in-class clinical trials for our clients.
One of our core technologies is the hyperinsulinemic euglycemic clamp. To be able to offer the best services for any glucose clamping setup, we have developed ClampArt, the next generation of glucose clamping.
We can recruit even the most complex clinical trials as Profil owns a continuously updated database with entries of more than 25.000 well characterized individuals (healthy, healthy at-risk, type 1 and type 2 diabetes) who are waiting to volunteer in our trials. In this webinar we will highlight all the services that offer and that make us the leading provider of clinical trials in the field.
Watch this webinar if you are planning clinical trials in the near future in order to learn why Profil is your partner of choice.
Meet the presenter
Dr. Lars Bochmann has an academic background in molecular medicine at the Wake Forest Institute for Regenerative Medicine in Winston-Salem (USA) and the European Molecular Biology Laboratory in Monterotondo (Italy). He joined Profil in 2015 as Director of Marketing & Business Development. Since then he has been responsible for all business development and general study inquiries. He is also your contact partner for Study Subject Recruitment, Online Seminars, Conferences and Events and News.